1,140 results match your criteria Uveitis Intermediate


Collaborative Ocular Tuberculosis Study (COTS) Consensus Guidelines on the Management of Tubercular Uveitis - Report 2: Guidelines for Initiating Anti-Tubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis and Retinal Vasculitis.

Ophthalmology 2020 Jun 27. Epub 2020 Jun 27.

Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address:

Topic: The Collaborative Ocular Tuberculosis Study (COTS), supported by the International Ocular Inflammation Society, International Uveitis Study Group and Foster Ocular immunological society, set up an international, expert-led consensus project to develop evidence and experience-based guidelines for the management of tubercular uveitis (TBU).

Clinical Relevance: The absence of international agreement on the use of anti-tubercular therapy (ATT) in patients with TBU contributes to a significant heterogeneity in the approach to the management of this condition.

Methods: Consensus statements for the initiation of ATT in TBU were generated using a two-step modified Delphi technique. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ophtha.2020.06.052DOI Listing

Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.

J Autoimmun 2020 Jun 22:102481. Epub 2020 Jun 22.

Ophthalmology Department, Hospital Charles Nicolle, Rouen, France; EA7510, UFR Santé, Rouen University, Rouen, France.

Objective: To compare the efficacy and safety of Disease-modifying antirheumatic drugs (DMARDs) and anti-TNF-α agents in patients with non-infectious non-anterior uveitis.

Methods: Single center retrospective study including adult patients with non-infectious intermediate, posterior or pan-uveitis. Outcomes were compared between patients treated with DMARDs or anti-TNF-α agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2020.102481DOI Listing

Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.

Ophthalmology 2020 Apr 3. Epub 2020 Apr 3.

Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California. Electronic address:

Purpose: To evaluate the efficacy and safety of intravitreal sirolimus in the management of noninfectious uveitis of the posterior segment (NIU-PS).

Design: Combined analysis of 2 phase 3, randomized, double-masked, multinational, 6-month studies.

Participants: Adults with active NIU-PS (intermediate uveitis, posterior uveitis, or panuveitis; defined as vitreous haze [VH] ≥1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ophtha.2020.03.033DOI Listing

Clinical utility of aqueous humor polymerase chain reaction and serologic testing for suspected infectious uveitis: a single-center retrospective study in South Korea.

BMC Ophthalmol 2020 Jun 19;20(1):242. Epub 2020 Jun 19.

Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 135-720, South Korea.

Background: This study aimed to assess and compare the clinical value of aqueous humor polymerase chain reaction (PCR) and serologic tests in patients diagnosed with suspected infectious uveitis.

Methods: In this retrospective observational study, data of 358 patients who were diagnosed with suspected infectious uveitis and who underwent aqueous humor PCR testing were analyzed. PCR and serologic test results were compared with the clinical features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-020-01513-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304133PMC
June 2020
1.075 Impact Factor

Inflammatory Choroidal Neovascular Membranes in Patients With Noninfectious Uveitis: The Place of Intravitreal Anti-VEGF Therapy.

Med Hypothesis Discov Innov Ophthalmol 2020 25;9(2):118-126. Epub 2020 Mar 25.

Department of Ophthalmology, Dokuz Eylul University Medical Faculty, İzmir, Turkey.

Inflammatory choroidal neovascularization (iCNV) is an infrequent but an important cause of visual morbidity in patients with non-infectious uveitis and mostly occurs in intermediate or posterior uveitis. Punctate inner choroiditis, Vogt-Koyanagi-Harada disease and multifocal choroiditis are among the leading causes of uveitis entities resulting in iCNVs. The diagnosis and management of iCNVs still remain a challenge. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134246PMC

Changing pattern of clinical manifestations of Behçet's disease in Tunisia: comparison between two decades.

Reumatologia 2020 30;58(2):87-92. Epub 2020 Apr 30.

Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Tunisia.

Objectives: To investigate the changes over time in extraocular and ocular manifestations of Behçet's disease (BD) in Tunisian patients.

Material And Methods: Retrospective study of 246 patients divided into two groups: group 1 (147 patients examined from 1995 to 2005) and group 2 (99 patients examined from 2006 to 2017).

Results: Active or scarred genital ulcers observed by physician at presentation were significantly less frequent in group 2 (47. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/reum.2020.95362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249524PMC

Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials.

Ocul Immunol Inflamm 2020 May 29:1-7. Epub 2020 May 29.

University of Montreal , Montreal, QC, Canada.

Purpose: To assess efficacy of adalimumab versus placebo in patients with active or inactive noninfectious intermediate, posterior, or panuveitis across different etiologies.

Methods: VISUAL I (V-I) and VISUAL II (V-II) clinical trials included adults with active or inactive uveitis, respectively, randomized to receive adalimumab or placebo. In a post hoc subgroup analysis, time to treatment failure (TTF) starting at week 6 (V-I) or week 2 (V-II) was analyzed using the Kaplan-Meier method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1757123DOI Listing

Pediatric Uveitis in a Referral Center in North Part of Turkey.

Ocul Immunol Inflamm 2020 May 28:1-5. Epub 2020 May 28.

Department of Ophthalmology, Ondokuz Mayis University, Samsun, Turkey.

: To analyze the demographic characteristics, clinical features, ocular complications, and visual outcome of pediatric patients with uveitis.: Retrospective evaluation of medical records.: The study included 156 eyes of 93 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1758158DOI Listing

Primary Vitreoretinal Lymphoma in HIV Infection.

Ocul Immunol Inflamm 2020 May 26:1-7. Epub 2020 May 26.

Eye and Vision Health, Flinders University, Adelaide, Australia.

: To describe the epidemiology, clinical characteristics, diagnosis and treatment of human immunodeficiency virus (HIV)-related primary vitreoretinal lymphoma (PVRL).: Narrative literature review.: HIV-related PVRL occurs in persons who are relatively young and generally have very low CD4+ T-cell counts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1751856DOI Listing

Epidemiology of 2000 Chinese uveitis patients from Northeast China.

Br J Ophthalmol 2020 May 18. Epub 2020 May 18.

Ophthalmologic Center, The Second Hospital of Jilin University, Changchun, China

Aims: To study the clinical characteristics of 2000 patients with uveitis admitted to the ophthalmology centre of the Second Hospital of Jilin University.

Methods: We retrospectively analysed 2000 patients with uveitis who were admitted to the uveitis clinic of the Second Hospital of Jilin University from July 2010 to June 2019 and analysed data on sex, onset age, onset season, anatomical classification, visual acuity and compared the results with those of other investigation studies.

Results: Among 2000 uveitis patients, the mean age of onset was 39. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bjophthalmol-2020-316256DOI Listing
May 2020
2.976 Impact Factor

Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis.

Mult Scler Relat Disord 2020 Jul 3;42:102152. Epub 2020 May 3.

Department of Emergency and Organ Transplantation, Rheumatology Unit, Bari, Italy.

Multiple sclerosis (MS) is a chronic demyelinating disorder of central nervous system (CNS) leading to neurological disability. A wide variety of ophthalmic and neuro-ophthalmic manifestations have been associated with MS. Although this link is well recognized, controversial is still the risk of developing MS in patients with ophthalmic manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2020.102152DOI Listing

Evaluation of factors for predicting risk of uveitis recurrence in Behcet's disease patients.

Braz J Med Biol Res 2020 8;53(6):e9118. Epub 2020 May 8.

Department of Rheumatology and Immunology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.

This study aimed to investigate the predictive factors for uveitis recurrence (UR) risk in Behcet's disease (BD) patients. BD patients (n=164) with a history of uveitis were recruited, and demographic data, clinical features, and laboratory tests were recorded. Uveitis was defined as anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis referring to the "International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431x20209118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228548PMC

Implications of pars planitis-associated cystoid macular edema on visual outcome and management in children.

Graefes Arch Clin Exp Ophthalmol 2020 Apr 28. Epub 2020 Apr 28.

Department of Ophthalmology, Hadassah Medical Center, POB 12000, 91120, Jerusalem, Israel.

Purpose: Pars planitis is a commonly observed type of pediatric uveitis. The aim of this study was to evaluate the implications of pars planitis-associated cystoid macular edema (CME) on visual outcome and treatment modalities.

Methods: A retrospective review of medical records in a single center with academic practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-020-04696-7DOI Listing

Ocular syphilis in Pacific peoples-are we making misdiagnoses secondary to yaws?

N Z Med J 2020 04 24;133(1513):53-60. Epub 2020 Apr 24.

Department of Ophthalmology, Auckland District Health Board, Auckland; Department of Ophthalmology, University of Auckland, Auckland.

Aims: To determine the demographic and clinical features of patients with ocular disease consistent with syphilis and positive treponemal serology in Auckland, and to compare patients who lived in a Pacific nation before 1960 with all other patients with regard to these features, considering a possible history of yaws infection.

Methods: Retrospective review of subjects seen in uveitis and neuroophthalmology clinics at Auckland District Health Board between January 2006 and June 2019.

Results: Two thousand four hundred and ninety-three subjects were reviewed in uveitis clinics during the timeframe, of whom 45 were diagnosed with syphilitic uveitis (1. Read More

View Article

Download full-text PDF

Source

Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer.

Am J Ophthalmol Case Rep 2020 Jun 7;18:100691. Epub 2020 Apr 7.

Bascom Palmer Eye Institute And, University of Miami Miller School of Medicine 900 NW 17th Street, Miami, FL, 33136, USA.

Purpose: To report a case of bilateral uveitis secondary to intravenous nivolumab therapy in a patient with stage IV non-small cell lung cancer.

Observations: A 53-year-old male with stage IV non-small cell lung cancer presented with gradual onset of blurry vision in the left eye for nine days after completion of the first cycle of intravenous nivolumab chemotherapy. At initial presentation, best-corrected visual acuity was 20/25 in the right eye and 20/30 in the left eye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajoc.2020.100691DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168346PMC

A case of adult-onset tubulointerstitial nephritis and uveitis syndrome presenting with granulomatous panuveitis.

Taiwan J Ophthalmol 2020 Jan-Mar;10(1):66-70. Epub 2020 Mar 4.

Department of Pathology, Hacettepe University, Ankara, Turkey.

The tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare disorder that is probably underdiagnosed in clinical practice. Ocular involvement in TINU syndrome not only presents with the nongranulomatous anterior uveitis in 80% of patients but also manifests as intermediate, posterior, or panuveitis. This case report mentions an adult male patient who presented with granulomatous iridocyclitis with panuveitis and mild renal insufficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/tjo.tjo_33_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158930PMC

[Intermediate Uveitis in Adults and Children - Update].

Klin Monbl Augenheilkd 2020 May 9;237(5):585-590. Epub 2020 Apr 9.

Augenzentrum am St. Franziskus-Hospital, Münster.

Intermediate uveitis is a rare disease. Interdiscliplinary investigations to identify or exclude an associated systemic disease (in Central Europe, this would primarily mean sarcoidosis and multiple sclerosis) should be initiated even at the first manifestation of disease. Therapy should be started in those patients with marked inflammatory activity or secondary complications and primarily encompasses local and systemic corticosteroids, although some patients need second line steroid sparing systemic DMARD therapy (DMARD: disease-modifying antirheumatic drug). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1111-9490DOI Listing

Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target.

Am J Ophthalmol Case Rep 2020 Jun 6;18:100646. Epub 2020 Mar 6.

Omics Laboratory, Stanford University, Palo Alto, CA, USA.

Purpose: To profile vitreous protein expression of intermediate uveitis (IU) patients.

Observations: We identified a mean of 363 ± 41 unique proteins (mean ± SD) in IU vitreous and 393 ± 69 unique proteins in control samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of liquid vitreous biopsies collected during pars plana vitrectomy. A total of 233 proteins were differentially expressed among control and IU samples, suggesting a protein signature that could distinguish the two groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajoc.2020.100646DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132169PMC

Characterization and Management of Inflammatory Eye Disease in Patients with Hidradenitis Suppurativa.

Ocul Immunol Inflamm 2020 Apr 7:1-6. Epub 2020 Apr 7.

Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

: To assess the spectrum and treatment outcomes of inflammatory eye disease (IED) in subjects with hidradenitis suppurativa (HS).: We conducted a single center retrospective chart review of 236 patients with HS seen for ophthalmic examination between 2013 and 2018.: Of 236 subjects with HS, 22 subjects (9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1739718DOI Listing

The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings.

Authors:
Rupesh Agrawal Ilaria Testi Sarakshi Mahajan Yew Sen Yuen Aniruddha Agarwal Andres Rousselot Dhananjay Raje Dinesh Visva Gunasekeran Onn Min Kon Talin Barisani-Asenbauer John H Kempen Amod Gupta Douglas A Jabs Justine R Smith Bahram Bodaghi Manfred Zierhut Marc DeSmet Peter Mc Cluskey Mamta Agarwal Manisha Agarwal Kanika Aggarwal Mukesh Agrawal Hassan Al-Dhibi Sofia Androudi Fatma Asyari Manohar Babu Balasundaram Kalpana Babu Murthy Edoardo Baglivo Alay Banker Reema Bansal Soumyava Basu Digamber Behera Jyotirmay Biswas Ester Carreño Laure Caspers Soon Phaik Chee Romi Chhabra Luca Cimino Luz Elena Concha Del Rio Emmett T Cunningham Andrè Luiz Land Curi Dipankar Das Ekaterina Denisova Alastair K Denniston Marie-Hélène Errera Alejandro Fonollosa Amala George Debra A Goldstein Yan Guex Crosier Avinash Gurbaxani Alessandro Invernizzi Hazlita M Isa Shah Md Islam Nicholas Jones Deeksha Katoch Moncef Khairallah Amit Khosla Michal Kramer Amitabh Kumar Atul Kumar Rina La Distia Nora Richard Lee Careen Lowder Saurabh Luthra Padmamalini Mahendradas Dorine Makhoul Shahana Mazumdar Salil Mehta Elisabetta Miserocchi Manabu Mochizuki Oli S Mohamed Cristina Muccioli Marion R Munk Somasheila Murthy Shishir Narain Heloisa Nascimento Piergiorgio Neri Myhanh Nguyen Annabelle A Okada Pinar Ozdal Alan Palestine Francesco Pichi S R Rathinam Ariel Schlaen Shobha Sehgal H Nida Sen Aman Sharma Kusum Sharma Samir S Shoughy Nirbhai Singh Ramandeep Singh Masoud Soheilian Sudharshan Sridharan Jennifer E Thorne Christoph Tappeiner Stephen Teoh Maria Sofia Tognon Ilknur Tugal-Tutkun Mudit Tyagi Harvey Uy Daniel Vitor Vasconcelos Santos Natasa Vidovic Valentincic Mark Westcott Ryoji Yanai Bety Yanez Alvarez Rahman Zahedur Quan Dong Nguyen Carlos Pavesio Vishali Gupta

Ocul Immunol Inflamm 2020 Apr 6:1-11. Epub 2020 Apr 6.

Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

An international, expert led consensus initiative was set up by the Collaborative Ocular Tuberculosis Study (COTS) group to develop systematic, evidence, and experience-based recommendations for the treatment of ocular TB using a modified Delphi technique process. In the first round of Delphi, the group identified clinical scenarios pertinent to ocular TB based on five clinical phenotypes (anterior uveitis, intermediate uveitis, choroiditis, retinal vasculitis, and panuveitis). Using an interactive online questionnaires, guided by background knowledge from published literature, 486 consensus statements for initiating ATT were generated and deliberated amongst 81 global uveitis experts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1716025DOI Listing
April 2020
1.440 Impact Factor

[Toxoplasmosis and behavioural changes (French translation of the article)].

Authors:
T Desmettre

J Fr Ophtalmol 2020 May 2;43(5):433-438. Epub 2020 Apr 2.

Centre de rétine médicale, 187, rue de Menin, 59520 Marquette-Lez-Lille, France; Queen Anne Street Medical Centre, 18-22, Queen Anne Street, W1G 8Hun London, Royaume-Uni. Electronic address:

Nearly one-third of the planet's population is affected by T. gondii infection. In ophthalmology, toxoplasmosis is even considered to be the most common cause of posterior uveitis of infectious origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2019.08.028DOI Listing

Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis.

Med Clin (Barc) 2020 Mar 18. Epub 2020 Mar 18.

Instituto de Biomedicina, Universidad de León (IBIOMED), León, España; Unidad de uveítis, Servicio de Oftalmología, Complejo Asistencial Universitario de León, León, España. Electronic address:

Objective: To generate recommendations on the use of immunomodulators in patients with non-infectious, non-neoplastic intermediate uveitis (IU), posterior uveitis (PU) and panuveitis (PanU) based on best evidence and experience.

Methods: A multidisciplinary panel of 5 experts was established, who defined the scope, users, and sections of the document. A systematic literature review (SLR) was performed to assess the efficacy and safety of immunomodulatory drugs in patients with non-infectious, non-neoplastic, non-anterior uveitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2019.10.023DOI Listing

Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.

Curr Opin Ophthalmol 2020 May;31(3):174-184

Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.

Purpose Of Review: Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis.

Recent Findings: An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICU.0000000000000651DOI Listing

Reply To: "Abd El Latif Et Al. Pattern of Intermediate Uveitis in an Egyptian Cohort".

Ocul Immunol Inflamm 2020 04 3;28(3):532. Epub 2020 Mar 3.

Department of Ophthalmology, University of Auckland, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1712434DOI Listing

Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.

Graefes Arch Clin Exp Ophthalmol 2020 May 29;258(5):1023-1030. Epub 2020 Feb 29.

Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA.

Purpose: To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis.

Methods: This was a retrospective study of patients with at least 12 months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-020-04614-xDOI Listing

Patterns of Uveitis in Egypt.

Ocul Immunol Inflamm 2020 Feb 18:1-10. Epub 2020 Feb 18.

Department of Ophthalmology at Faculty of Medicine, Cairo University, Giza, Egypt.

: To investigate the clinical patterns of uveitis patients presenting to the uveitis clinic at Cairo University hospitals.: A retrospective study was conducted on 313 cases of uveitis from May 2015 to May 2017. Patients had detailed ocular and medical examinations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1714060DOI Listing
February 2020

Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis.

Ocul Immunol Inflamm 2020 Feb 14:1-5. Epub 2020 Feb 14.

Department of Ophthalmology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

: To describe the results of tocilizumab treatment in children with refractory non-anterior uveitis.: A case series of seven children with refractory non-anterior uveitis (onset ≤16 years) with leakage on fluorescein angiogram (FA) were treated with tocilizumab intravenously every 4 weeks (eight mg/kg). Minimum follow-up was 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2020.1712431DOI Listing
February 2020

Use of Anti-Tumour Necrosis Factor-Alpha Agents in the Management of HLA-B-27-Associated Uveitis: The First Case Series from India.

Ocul Immunol Inflamm 2020 Feb 14:1-5. Epub 2020 Feb 14.

Department of Uvea, Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, India.

: The aim of this study was to evaluate the efficacy of adalimumab (ADL) and golimumab (GLM) in patients with HLA-B-27-associated uveitis.: We conducted a retrospective analysis of patients with HLA-B-27-associated uveitis who had received subcutaneous GLM and ADL between 2014 and 2018.: The study included 14 patients, 12 of whom received subcutaneous ADL and two patients were treated with subcutaneous GLM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1698754DOI Listing
February 2020

Pattern of uveitis in a tertiary eye care center of central India: Results of a prospective patient database over a period of two years.

Indian J Ophthalmol 2020 03;68(3):476-481

Department of Ophthalmology, Gandhi Medical College, Bhopal, Madhya Pradesh, India.

Purpose: To identify the pattern of uveitis at a tertiary eye center in the central India and to compare with other reported studies.

Methods: This prospective observational study was undertaken with all new uveitis cases attending the uvea clinic between January 2016 and September 2017. A standard clinical protocol and detailed investigations were done to find out the specific cause of uveitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijo.IJO_1724_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043162PMC

Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial.

Trials 2020 Feb 10;21(1):159. Epub 2020 Feb 10.

Department of Ophthalmology, CHU Nantes, Nantes, France.

Background: Whether they are injected peri- or intraocularly, corticosteroids are still essential tools in the therapeutic arsenal for treating inflammatory macular oedema. A few years ago, however, only triamcinolone acetonide was available to ophthalmologists. While this compound was initially developed for rheumatological or dermatological use, it has been increasingly deployed in ophthalmology, despite still being off-label. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-020-4066-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011383PMC
February 2020

Comparative study of arsenic toxicosis and ocular pathology in wild muskrats (Ondatra zibethicus) and red squirrels (Tamiasciurus hudsonicus) breeding in arsenic contaminated areas of Yellowknife, Northwest Territories (Canada).

Chemosphere 2020 Jun 25;248:126011. Epub 2020 Jan 25.

Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada.

The Giant Mine is an abandoned gold mine in Yellowknife, Northwest Territories, Canada. Throughout its operation from 1948 to 2004, the Giant Mine released heavy amounts of arsenic trioxide into the environment, thus contaminating the soil and surface water within and around the vicinity of the mine site. Chronic arsenic (As) poisoning negatively impacts wildlife health and can induce multi-organ damages including neurodegeneration and visual dysfunction depending on concentration and duration of exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chemosphere.2020.126011DOI Listing

Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis.

Jpn J Ophthalmol 2020 Mar 3;64(2):150-159. Epub 2020 Feb 3.

Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan.

Purpose: Retinal vasculitis and occlusive changes are important signs of posterior uveitis and are possible diagnostic markers for uveitis. However, the frequency of arteritis and phlebitis in various uveitis entities, including infectious uveitis (IU) and non-infectious uveitis (NIU), have not been systematically investigated.

Study Design: Retrospective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10384-020-00717-4DOI Listing

Multimodal imaging in intermediate tuberculous uveitis.

Arch Soc Esp Oftalmol 2020 May 29;95(5):e37-e38. Epub 2020 Jan 29.

Departamento de Salud Valencia La Fe, Hospital Universitari i Politècnic La Fe, Valencia, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oftal.2019.12.006DOI Listing

INTERMEDIATE UVEITIS WITH RETINAL DETACHMENT IN A PATIENT WITH POMPE DISEASE.

Retin Cases Brief Rep 2020 Jan 28. Epub 2020 Jan 28.

Duke University Eye Center, Durham, North Carolina.

Purpose: To describe the ocular findings in a patient with glycogen storage disease II (Pompe disease).

Methods: Case report.

Results: A 14-year-old boy with Pompe disease was referred for evaluation of a retinal detachment in the left eye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICB.0000000000000971DOI Listing
January 2020

Toxoplasmosis and behavioural changes.

Authors:
T Desmettre

J Fr Ophtalmol 2020 Mar 21;43(3):e89-e93. Epub 2020 Jan 21.

Centre de rétine médicale, 187, rue de Menin, 59520 Marquette-Lez-Lille, France; Queen Anne Street Medical Centre, 18-22, Queen Anne Street, W1G 8Hun, London, United Kingdom. Electronic address:

Nearly one-third of the planet's population is affected by Toxoplasma gondii infection. In ophthalmology, toxoplasmosis is even considered to be the most common cause of posterior uveitis of infectious origin. Humans are only an intermediate host and T. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2020.01.001DOI Listing

Intermediate Uveitis Associated with Tattooing of Eyebrows as a Manifestation of Systemic Sarcoidosis: Report of Two Cases.

Ocul Immunol Inflamm 2020 Jan 16:1-4. Epub 2020 Jan 16.

Farabi Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Permanent make-up tattooing as a cosmetic procedure is gaining popularity especially among women. Although it is considered a relatively safe intervention, the ink used can rarely be a trigger of sarcoidosis. Uveitis can occur as part of this inflammatory process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1699581DOI Listing
January 2020

Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence.

J Ophthalmic Inflamm Infect 2020 Jan 10;10(1). Epub 2020 Jan 10.

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Background: This study aims to determine if the intravitreal dexamethasone implant (DEX implant, Ozurdex; Allergan, Inc., Irvine, California) is effective for treating intermediate, posterior, and panuveitis as a monotherapy or adjunctive treatment to systemic immunomodulatory therapies.

Methods: A systematic review using MEDLINE, EMBASE, and PubMed database searches was conducted with the Oxford Centre for Evidence-based Medicine Levels of Evidence criteria to select publications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12348-019-0189-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954157PMC
January 2020

Cytopathology and Polymerase Chain Reaction of Vitreous Fluid in Tubercular Intermediate Uveitis.

Ocul Immunol Inflamm 2020 Jan 6:1-3. Epub 2020 Jan 6.

Department of Uveitis and Ocular Pathology, Medical Research Foundation, Sankara Nethralaya, Chennai, India.

: Cytopathology of vitreous is most commonly done to diagnose vitreoretinal lymphoma in eyes with nonspecific inflammation. Vitreous cytopathology features of tuberculous intermediate uveitis have not been described in literature.: We report a case of a healthy 35-year-old female who showed granulomatous inflammatory changes on vitreous cytopathology with polymerase chain reaction confirming a diagnosis of intraocular tuberculosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1697825DOI Listing
January 2020

Risk factors for ocular complications in adult patients with uveitis.

Eur J Ophthalmol 2020 Jan 5:1120672119899379. Epub 2020 Jan 5.

Department of Ophthalmology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.

Purpose: To report risk factors for ocular complications in adults with uveitis.

Methods: Retrospective cohort study of 653 patients with uveitis (869 eyes) followed up for at least 1 month attended between May 1989 and December 2012.

Results: After a median follow-up of 16 months (interquartile range = 3-59), 43. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1120672119899379DOI Listing
January 2020

Visual Acuity Outcome over Time in Non-Infectious Uveitis.

Ocul Immunol Inflamm 2019 Dec 10:1-8. Epub 2019 Dec 10.

Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population.: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1687733DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282970PMC
December 2019

[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis].

J Fr Ophtalmol 2020 Apr 6;43(4):341-361. Epub 2019 Dec 6.

Service d'ophtalmologie, hôtel Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes, France.

Controlling long-term inflammation during non-infectious intermediate, posterior or panuveitis while limiting side effects remains challenging. There is no standardized pre-therapeutic evaluation providing diagnostic certainty, but some simple tests allow us to identifiy the main etiologies. The ophthalmologist identifies the type of uveitis, and the internist completes the investigations according to the ophthalmologist's findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2019.03.033DOI Listing

[Uveitis: Diagnosis and work-up].

Authors:
C Bonnet A Brézin

J Fr Ophtalmol 2020 Feb 5;43(2):145-151. Epub 2019 Dec 5.

Pôle de Paris, service d'ophtalmologie, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg St Jacques, 75014 Paris, France.

Uveitis is an inflammation of the uveal tissue: iris, ciliary body and choroid. The annual incidence of uveitis in France is low (17/100,000), but visual and therapeutic consequences may be severe. Etiologic investigation is thus a fundamental step in the management of any uveitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2019.03.038DOI Listing
February 2020

Response: comment on 'Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis': Letter to the Editor.

Acta Ophthalmol 2020 05 26;98(3):e392-e393. Epub 2019 Nov 26.

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aos.14318DOI Listing

Bilateral Anterior and Intermediate Uveitis Associated With Omeprazole.

Ann Pharmacother 2020 Apr 19;54(4):397-399. Epub 2019 Nov 19.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019890093DOI Listing
April 2020
4 Reads

Comment on 'Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis'.

Acta Ophthalmol 2020 05 17;98(3):e390-e392. Epub 2019 Nov 17.

Department of Ophthalmology, University of Bonn, Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aos.14309DOI Listing

Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis.

Ocul Immunol Inflamm 2019 Nov 11:1-12. Epub 2019 Nov 11.

Rheumatology Department and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

: To estimate the incidence rate (IR) and identify risk factors associated to inflammatory relapse after immunosuppressive drug (ISD) discontinuation in noninfectious uveitis patients.: Multicenter longitudinal retrospective study, including patients from four uveitis clinics followed-up until December 2018. Hazard ratios for different variables were estimated using multivariable Cox models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1681469DOI Listing
November 2019

The Detection of Occult Retinal Vasculitis on Fluorescein Angiography in Pediatric Uveitis.

Ophthalmol Retina 2020 02 20;4(2):198-203. Epub 2019 Sep 20.

University of Texas Southwestern Medical Center, Department of Ophthalmology, Dallas, Texas; Children's Medical Center Dallas, Department of Ophthalmology, Dallas, Texas. Electronic address:

Purpose: To evaluate the usefulness of fluorescein angiography (FA) to detect occult retinal vasculitis in children with otherwise apparently quiescent intermediate uveitis, posterior uveitis, and panuveitis based on clinical examination alone.

Design: Retrospective chart review.

Participants: Pediatric uveitis patients evaluated at the Children's Medical Center in Dallas, Texas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oret.2019.09.007DOI Listing
February 2020

The Clinical Characteristics of Pediatric Non-Infectious Uveitis in Two Tertiary Referral Centers in Turkey.

Ocul Immunol Inflamm 2019 Nov 5:1-8. Epub 2019 Nov 5.

Department of Ophthalmology, Ankara University, Ankara, Turkey.

: To report the manifestations, patterns of disease, treatment strategies and outcomes in pediatric patients with noninfectious uveitis.: Demographic information of 76 cases was recorded. Symptoms, anatomic location, laterality, visual acuity (VA), intraocular pressure, associated systemic diseases, therapeutic strategies, side effects, complications were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1674890DOI Listing
November 2019

Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis.

Ocul Immunol Inflamm 2019 Oct 31:1-9. Epub 2019 Oct 31.

Department of Internal Medicine, Cochin Hospital, Paris, France.

: This study aimed to assess the diagnostic relevance of CD4/CD8 ratio in cerebrospinal fluid (CSF) for the etiological diagnosis work-up of uveitis.: We consecutively included patients who were referred to our department for the diagnostic workup of intermediate and/or posterior uveitis. Etiological diagnoses were established in a blind manner regarding CD4/CD8 ratio. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1678647DOI Listing
October 2019